Introduction: Essential hypertension is a multifactorial disease. Many experimental studies have elucidated the role of oxidative stress and atherosclerosis in the pathogenesis of essential hypertension. Apolipoprotein E is a plasma protein that is found to have antioxidant properties, and it also protects against atherosclerosis. Interestingly, the biological function of apolipoprotein E is strongly affected by polymorphisms in its gene. Based on this evidence, our aim was to investigate the association of apolipoprotein E gene polymorphisms with essential hypertension. Methods: This study was conducted on 70 hypertensive patients and 73 control participants recruited from the Balok governmental health clinic in Kuantan, Pahang. The polymerase chain reaction restriction fragment length polymorphism assay (PCR-RFLP) was used for determination of the apolipoprotein E genotype. Our results were also verified later by direct sequencing of the amplicons. Results: There was no significant association of apolipoprotein E allele or genotype frequencies with hypertensive disease or blood pressure levels, although the E4 allele was slightly more frequent in the hypertensive patients than in the control group (OR=1.055; 0.471-2.359, CI 95%). To improve the precision of the study and to settle the controversies among similar studies meta-analysis was performed; however it revealed a net nonsignificant association between the apolipoprotein E4 allele with essential hypertension in the combined population. Conclusion: Our data and the meta-analysis findings provide evidence that apolipoprotein E gene polymorphism has no direct significant association with hypertension.

Individuals with metabolic syndrome are at increased risk for developing cardiovascular disease and diabetes mellitus. This study was carried out to determine the prevalence of metabolic syndrome and clinical characteristics in hypertensive patients according to the criteria of the new International Diabetes Federation (IDF) definition. Hypertensive patients were recruited from the Medical Out-Patient Department, Kuantan Hospital. The five components of metabolic syndrome were examined which included blood pressure (? 130/85 mmHg), fasting glucose (? 5.6mmol/L), fasting triglycerides (? 1.7 mmol/L), high-density lipoprotein (HDL) cholesterol level (< 1.03mmol/L in males and < 1.29mmol/L in females), and abdominal obesity (waist circumference: men > 90cm; women > 80cm). Out of 139 hypertensive patients, there were 113 met all the selection criteria consisted of 61 male and 52 female subjects. The participants' age ranged from 21 to 91 years (51.9�16.8 years; mean�SD), and body mass index 13.5-42.3 kg/m2 (27.5�4.9 kg/m2). According to the IDF criteria, the prevalence of central obesity was 67.2% in men and 84.6% in women. Among the 113 hypertensive subjects over 21 years of age, 51 subjects or 45.1% had metabolic syndrome. The present data revealed that there was high prevalence of metabolic syndrome in Malaysian hypertensive subjects. This finding was supported by the fact of high prevalence of central obesity among the study subjects.